Complementary Elements to the Pathogenesis, Early Detection and Second Line Antihormonal Therapy of Prostate Cancer

Tamás Kullmann

doi:10.31083/j.jomh1807155

Article Menu

Export Article

Article Data

Views 2411
Dowloads 129

Editorial

Open Access Special Issue

Complementary Elements to the Pathogenesis, Early Detection and Second Line Antihormonal Therapy of Prostate Cancer

Tamás Kullmann^1,*,

¹Department of Oncoradiology, Petz Aladár Hospital, 9024 Győr, Hungary

DOI: 10.31083/j.jomh1807155 Vol.18,Issue 7,July 2022 pp.1-2

Published: 31 July 2022

(This article belongs to the Special Issue Therapy and prognosis of metastatic prostate cancer)

*Corresponding Author(s): Tamás Kullmann E-mail: kullmanndoki@hotmail.com

PDF (160.04 kB) View Full-text

Cite and Share

Tamás Kullmann. Complementary Elements to the Pathogenesis, Early Detection and Second Line Antihormonal Therapy of Prostate Cancer. Journal of Men's Health. 2022; 18(7): 1-2. doi: 10.31083/j.jomh1807155

URL:

https://www.jomh.org/articles/10.31083/j.jomh1807155

References

[1] Sun X, Kour BD, Wang X, Hu X, Wang Y, Sugunakar VJ. In-sights into association between urolithiasis and prostate cancer. Journal of Men’s Health. 2021; 17: 52–61.

[2] Datta D, Aftabuddin M, Kundu R, Baid M, Das SK, Sarkar S, et al. A comprehensive mechanistic basis of prostate cancer ad-vancement & its personalized implementation-bridging the gap: present state and future prospect. Journal of Men’s Health. 2021; 17: 18–35.

[3] Lewis-Thames MW, Khan S, Hicks V, Drake BF. Predictors of annual prostate-specific antigen (PSA) screening among black men: results from an urban community-based prostate cancer screening program. Journal of Men’s Health. 2021; 17: 78–83.

[4] Porav-Hodade D, Balan D, Gherasim R, Vida OA, Todea-Moga C, Voidazan S, et al. Decrease in prostate cancer detection during COVID-19 pandemic. Journal of Men’s Health. 2021; 17: 151–155.

[5] Alkan A, Güç ZG, Gürbüz M, Özgün G, Değirmencioğlu S, Doğan M, et al. Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate can-cer in geriatric (≥75) patients. Journal of Men’s Health. 2021; 17: 128–134.

[6] Yang X, Shan J, Zhang Q, Yuan Z, Xu H, Liu Z, et al. The diag-nostic value of a new formula combining age and prostate vol-ume in prostate cancer. Journal of Men’s Health. 2022; 18: 29.

[7] András S, Károly K, Adél A, Noémi K, Zsolt S, Tamás K. A single centre pilot experience with 18F-JK-PSMA-7 PET-CT in the staging of prostate cancer. Journal of Men’s Health. 2022; 18: 45.

[8] Tamás K, Károly K, Adél A, Noémi K, Ágnes H, Zsolt S. Op-timisation of second line antihormonal treatment for castration resistant metastatic prostate cancer. Journal of Men’s Health. 2022; 18: 93.

[9] Khader AA, Nsour E, Edwan TA. Prostatic signet-ring adeno-carcinoma: a case report. Journal of Men’s Health. 2022; 18: 90.

[10] Kullmann T, András S, Noémi K, Zsolt S. Neuroendocrine can-cer of the prostate. Two case reports. Journal of Men’s Health. 2022; 18: 065.

[11] Fang H, He L, He H, Wang X, Wang Y, Ge H, et al. The 100 most-cited articles in castration-resistant prostate cancer: a bib-liometric analysis. Journal of Men’s Health. 2022; 18: 3.

[12] Hurst R, Meader E, Gihawi A, Rallapalli G, Clark J, Kay GL, et al. Microbiomes of Urine and the Prostate are Linked to Hu-man Prostate Cancer Risk Groups. European Urology Oncology. 2022. (in press)